ANIP
ANI PHARMACEUTICALS INC
- Latest sale
- $385k
- Nov 18 · Routine
- Form 4 sales
- 185
- On record
- Form 144 notices
- 34
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineAug 13 2026
Sold 500 shares at $75.48 ($38k)
Cook Meredith, SR. VP, GENERAL COUNSEL & SEC.
10b5-1 planSold 0.7% of holdings ($5.7M position)74,424 shares left1.3x usual sizeFiling
- 2 Form 4 saleRoutineAug 25 +12 days
Sold 5,400 shares at $74.30 ($401k)
Lalwani Nikhil, PRESIDENT & CEO
10b5-1 planSold 1.5% of holdings ($26M position)344,489 shares left0.1x usual sizeFiling
- 3 Form 4 saleRoutineAug 31 +6 days
Sold 2,850 shares at $72.80 ($207k)
Carey Stephen P., SVP & CFO
10b5-1 planSold 1.6% of holdings ($12.7M position)171,843 shares left0.9x usual sizeFiling
- 4 Form 4 saleRoutineSep 11 +11 days
Sold 1,000 shares at $71.53 ($72k)
Thoma Jeanne, Director
10b5-1 planSold 3.6% of holdings ($2M position)26,762 shares leftFiling
- 5 Form 4 saleRoutineSep 14 +3 days
Sold 500 shares at $70.79 ($35k)
Cook Meredith, SR. VP, GENERAL COUNSEL & SEC.
10b5-1 planSold 0.7% of holdings ($5.3M position)73,924 shares left1.3x usual sizeFiling
- 6 Form 4 saleRoutineSep 15 +1 day
Sold 5,400 shares at $71.00 ($383k)
Lalwani Nikhil, PRESIDENT & CEO
10b5-1 planSold 1.6% of holdings ($24.5M position)339,089 shares left0.1x usual sizeFiling
- 7 Form 4 saleRoutineSep 29 +14 days
Sold 2,850 shares at $73.00 ($208k)
Carey Stephen P., SVP & CFO
10b5-1 planSold 1.7% of holdings ($12.5M position)168,993 shares left0.9x usual sizeFiling
- 8 Form 4 saleRoutineNov 18 +50 days
Sold 5,400 shares at $71.22 ($385k)
Lalwani Nikhil, PRESIDENT & CEO
10b5-1 planSold 1.6% of holdings ($23.8M position)328,289 shares left0.2x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (219)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 5,400 | $385k | 1.6% | Routine | SEC |
| Sep 29, 2026 | Carey Stephen P. | SVP & CFO | Form 4 sale | 2,850 | $208k | 1.7% | Routine | SEC |
| Sep 15, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 5,400 | $383k | 1.6% | Routine | SEC |
| Sep 14, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $35k | 0.7% | Routine | SEC |
| Sep 11, 2026 | Thoma Jeanne | Director | Form 4 sale | 1,000 | $72k | 3.6% | Routine | SEC |
| Aug 31, 2026 | Carey Stephen P. | SVP & CFO | Form 4 sale | 2,850 | $207k | 1.6% | Routine | SEC |
| Aug 25, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 5,400 | $401k | 1.5% | Routine | SEC |
| Aug 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $38k | 0.7% | Routine | SEC |
| Aug 10, 2026 | Gutwerg Ori | SVP, GENERICS | Form 4 sale | 3,162 | $243k | 4.0% | No plan | SEC |
| Jul 29, 2026 | Carey Stephen P. | SVP & CFO | Form 4 sale | 2,850 | $232k | 1.6% | Routine | SEC |
| Jul 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $41k | 0.6% | Routine | SEC |
| Jul 2, 2026 | Carey Stephen P. | SVP & CFO | Form 4 sale | 3,313 | $285k | 1.8% | Routine | SEC |
| Jun 29, 2026 | Carey Stephen P. | SVP & CFO | Form 4 sale | 2,850 | $240k | 1.6% | Routine | SEC |
| Jun 12, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $41k | 0.6% | Routine | SEC |
| Jun 8, 2026 | Haughey Thomas | Director | Form 4 sale | 2,000 | $162k | 4.9% | Routine | SEC |
| Jun 5, 2026 | Carey Stephen P. | SVP & CFO | Form 4 sale | 3,312 | $265k | 1.8% | Routine | SEC |
| May 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $39k | 0.6% | Routine | SEC |
| May 13, 2026 | Walsh Patrick D | Director | Form 4 sale | 13,973 | $1.1M | 26.7% | Unusual | SEC |
| May 12, 2026 | Gutwerg Ori | SVP, GENERICS | Form 4 sale | 2,772 | $220k | 3.4% | No plan | SEC |
| May 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Form 4 sale | 459 | $36k | 1.2% | No plan | SEC |
| May 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 55,000 | $4.3M | 13.6% | No plan | SEC |
| Apr 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $39k | 0.6% | Routine | SEC |
| Mar 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $36k | 0.6% | Routine | SEC |
| Mar 13, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 3,162 | $227k | 3.3% | Routine | SEC |
| Mar 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Form 4 sale | 4,772 | $357k | 11.0% | No plan | SEC |
| Mar 9, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 6,572 | $488k | 11.2% | Unusual | SEC |
| Mar 9, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 5,723 | $425k | 5.7% | Routine | SEC |
| Mar 5, 2026 | Carey Stephen P. | SVP & CFO | Form 4 sale | 7,312 | $552k | 3.8% | No plan | SEC |
| Mar 3, 2026 | Gutwerg Ori | SVP, GENERICS | Form 4 sale | 2,060 | $158k | 2.4% | No plan | SEC |
| Mar 3, 2026 | Walsh Patrick D | Director | Form 4 sale | 6,000 | $445k | 10.3% | No plan | SEC |
| Mar 2, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 417 | $31k | 0.4% | Routine | SEC |
| Feb 20, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 3,814 | $296k | 7.2% | Unusual | SEC |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 5,323 | $415k | 5.9% | Routine | SEC |
| Feb 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $38k | 0.7% | Routine | SEC |
| Feb 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 7,032 | $538k | 7.1% | Routine | SEC |
| Jan 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 500 | $42k | 0.7% | Routine | SEC |
| Dec 18, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 1,622 | $134k | 2.7% | Routine | SEC |
| Dec 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $33k | 0.5% | Routine | SEC |
| Dec 5, 2025 | Tannenbaum Renee P | Director | Form 4 sale | 1,800 | $146k | 6.7% | No plan | SEC |
| Nov 13, 2025 | Walsh Patrick D | Director | Form 4 sale | 8,643 | $751k | 12.3% | No plan | SEC |
| Nov 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $35k | 0.5% | Routine | SEC |
| Nov 13, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 14,736 | $1.3M | 8.5% | No plan | SEC |
| Oct 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $36k | 0.5% | Routine | SEC |
| Sep 19, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 1,000 | $98k | 1.6% | Routine | SEC |
| Sep 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $39k | 0.5% | Routine | SEC |
| Sep 3, 2025 | Pera Antonio R | Director | Form 4 sale | 7,292 | $692k | 24.3% | No plan | SEC |
| Aug 25, 2025 | Leonard Matthew J | Director | Form 4 sale | 2,528 | $229k | 26.9% | Unusual | SEC |
| Aug 22, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 1,763 | $161k | 2.7% | No plan | SEC |
| Aug 21, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 100,000 | $9M | 18.8% | Unusual | SEC |
| Aug 20, 2025 | Pera Antonio R | Director | Form 4 sale | 5,421 | $486k | 15.3% | No plan | SEC |
| Aug 18, 2025 | Thoma Jeanne | Director | Form 4 sale | 21,540 | $1.9M | 47.9% | Unusual | SEC |
| Aug 18, 2025 | Leonard Matthew J | Director | Form 4 sale | 6,937 | $612k | 42.5% | Unusual | SEC |
| Aug 15, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.7M | 10.4% | No plan | SEC |
| Aug 15, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 100,000 | $8.8M | 15.8% | Unusual | SEC |
| Aug 15, 2025 | Walsh Patrick D | Director | Form 4 sale | 9,000 | $801k | 11.4% | No plan | SEC |
| Aug 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $36k | 0.5% | Routine | SEC |
| Aug 12, 2025 | Gutwerg Ori | SVP, GENERICS | Form 4 sale | 5,873 | $508k | 6.5% | No plan | SEC |
| Aug 12, 2025 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 56,960 | $4.9M | 12.2% | No plan | SEC |
| Aug 12, 2025 | Carey Stephen P. | SVP & CFO | Form 4 sale | 50,000 | $4.3M | 21.7% | Unusual | SEC |
| Aug 12, 2025 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Form 4 sale | 4,975 | $426k | 10.9% | No plan | SEC |
| Aug 12, 2025 | Haughey Thomas | Director | Form 4 sale | 19,341 | $1.7M | 34.6% | Unusual | SEC |
| Jul 14, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $26k | 0.5% | Routine | SEC |
| Jun 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $25k | 0.5% | Routine | SEC |
| May 15, 2025 | Gutwerg Ori | SVP, GENERICS | Form 4 sale | 881 | $53k | 1.0% | No plan | SEC |
| May 14, 2025 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 4,000 | $242k | 3.6% | No plan | SEC |
| May 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $25k | 0.5% | Routine | SEC |
| May 9, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 700 | $54k | 0.1% | Routine | SEC |
| Apr 14, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $28k | 0.5% | Routine | SEC |
| Mar 19, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 1,866 | $121k | 2.8% | Routine | SEC |
| Mar 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $25k | 0.5% | Routine | SEC |
| Mar 7, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 1,000 | $61k | 1.5% | Routine | SEC |
| Mar 5, 2025 | Gutwerg Ori | SVP, GENERICS | Form 4 sale | 5,384 | $323k | 5.4% | No plan | SEC |
| Feb 21, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 1,000 | $60k | 1.4% | Routine | SEC |
| Feb 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $24k | 0.5% | Routine | SEC |
| Jan 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 400 | $22k | 0.7% | Routine | SEC |
| Dec 17, 2024 | Carey Stephen P. | SVP & CFO | Form 4 sale | 7,500 | $418k | 4.6% | No plan | SEC |
| Dec 17, 2024 | Carey Stephen P. | Officer | Form 144 notice | 7,500 | $414k | Notice | SEC | |
| Dec 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $14k | 0.4% | Routine | SEC |
| Dec 11, 2024 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 1,000 | $60k | 2.0% | Routine | SEC |
| Nov 26, 2024 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 33,481 | $1.9M | 8.3% | No plan | SEC |
| Nov 26, 2024 | Lalwani Nikhil | Officer | Form 144 notice | 33,481 | $1.9M | Notice | SEC | |
| Nov 15, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 6,500 | $375k | 7.8% | No plan | SEC |
| Nov 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $15k | 0.4% | Routine | SEC |
| Oct 14, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $14k | 0.4% | Routine | SEC |
| Sep 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $14k | 0.4% | Routine | SEC |
| Aug 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $15k | 0.4% | Routine | SEC |
| Jul 18, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 2,743 | $170k | 0.4% | Routine | SEC |
| Jul 17, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 47,257 | $3M | 6.9% | Routine | SEC |
| Jul 12, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $16k | 0.4% | Routine | SEC |
| Jul 1, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.3M | 9.4% | Routine | SEC |
| Jun 21, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 20,000 | $1.2M | 2.8% | Routine | SEC |
| Jun 20, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 30,000 | $1.8M | 4.1% | Routine | SEC |
| Jun 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $16k | 0.4% | Routine | SEC |
| Jun 5, 2024 | Gutwerg Ori | SVP, GENERICS | Form 4 sale | 2,985 | $200k | 3.7% | No plan | SEC |
| Jun 4, 2024 | Carey Stephen P. | SVP & CFO | Form 4 sale | 5,000 | $318k | 3.0% | No plan | SEC |
| Jun 3, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.3M | 8.6% | Routine | SEC |
| May 21, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 2,000 | $123k | 2.3% | No plan | SEC |
| May 20, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 12,855 | $795k | 1.7% | Routine | SEC |
| May 17, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 37,145 | $2.4M | 4.7% | Routine | SEC |
| May 16, 2024 | Tannenbaum Renee P | Director | Form 4 sale | 2,000 | $128k | 9.9% | No plan | SEC |
| May 14, 2024 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 16,669 | $1.1M | 4.2% | No plan | SEC |
| May 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $17k | 0.4% | Routine | SEC |
| May 1, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.3M | 7.9% | Routine | SEC |
| Apr 19, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 27,232 | $1.8M | 3.4% | Routine | SEC |
| Apr 17, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 22,768 | $1.5M | 2.7% | Routine | SEC |
| Apr 12, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $17k | 0.4% | Routine | SEC |
| Apr 1, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.3M | 7.3% | Routine | SEC |
| Mar 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $17k | 0.4% | Routine | SEC |
| Mar 11, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.3M | 6.8% | Routine | SEC |
| Mar 11, 2024 | Carey Stephen P. | SVP & CFO | Form 4 sale | 7,787 | $510k | 4.2% | No plan | SEC |
| Mar 8, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 10,000 | $672k | 1.2% | Routine | SEC |
| Mar 8, 2024 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 45,257 | $3M | 9.9% | No plan | SEC |
| Mar 7, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 40,000 | $2.6M | 4.5% | Routine | SEC |
| Mar 7, 2024 | Marken James G. | SVP OPS & PROD DEV | Form 4 sale | 24,338 | $1.6M | 16.4% | No plan | SEC |
| Mar 5, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 5,000 | $330k | 5.4% | No plan | SEC |
| Mar 4, 2024 | Pera Antonio R | Director | Form 4 sale | 7,000 | $456k | 20.8% | No plan | SEC |
| Feb 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $14k | 0.7% | Routine | SEC |
| Jan 23, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 25,216 | $1.4M | 2.8% | Routine | SEC |
| Jan 18, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 24,784 | $1.4M | 2.7% | Routine | SEC |
| Jan 12, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $14k | 0.7% | Routine | SEC |
| Dec 19, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 50,000 | $2.6M | 5.1% | Routine | SEC |
| Dec 11, 2023 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $12k | 0.7% | Routine | SEC |
| Nov 17, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 13,000 | $663k | 1.3% | Routine | SEC |
| Nov 17, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 13,000 | $663k | Notice | SEC | |
| Nov 16, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 6,448 | $333k | Notice | SEC | |
| Nov 16, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 36,190 | $1.9M | 3.5% | Routine | SEC |
| Nov 15, 2023 | Davis Krista | SVP, CHIEF HR OFFICER | Form 4 sale | 2,622 | $141k | 7.4% | No plan | SEC |
| Nov 15, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 7,647 | $410k | Notice | SEC | |
| Nov 14, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 22,905 | $1.2M | Notice | SEC | |
| Nov 13, 2023 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Form 4 sale | 250 | $13k | 0.7% | Routine | SEC |
| Nov 10, 2023 | Mutz Christopher | HEAD OF RARE DISEASE | Form 4 sale | 3,000 | $157k | 4.5% | No plan | SEC |
| Oct 19, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 25,000 | $1.4M | 2.4% | Routine | SEC |
| Oct 19, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 10,000 | $571k | Notice | SEC | |
| Oct 18, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 6,242 | $361k | Notice | SEC | |
| Oct 17, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 8,758 | $513k | Notice | SEC | |
| Oct 16, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 25,000 | $1.4M | 2.3% | Routine | SEC |
| Oct 16, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 13,063 | $762k | Notice | SEC | |
| Oct 13, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 11,937 | $687k | Notice | SEC | |
| Oct 2, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.1M | 6.4% | Routine | SEC |
| Sep 19, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 50,000 | $3.1M | 4.4% | Routine | SEC |
| Sep 19, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 25,333 | $1.6M | Notice | SEC | |
| Sep 18, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 8,425 | $519k | Notice | SEC | |
| Sep 15, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 16,242 | $1M | Notice | SEC | |
| Sep 1, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.3M | 6.0% | Routine | SEC |
| Aug 29, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 50,000 | $3.2M | 4.2% | No plan | SEC |
| Aug 29, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 25,000 | $1.6M | Notice | SEC | |
| Aug 28, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 25,000 | $1.6M | Notice | SEC | |
| Aug 23, 2023 | Gutwerg Ori | SVP, GENERICS | Form 4 sale | 15,561 | $971k | 20.3% | No plan | SEC |
| Aug 23, 2023 | Marken James G. | SVP OPS & PROD DEV | Form 4 sale | 3,932 | $248k | 2.9% | No plan | SEC |
| Aug 18, 2023 | Brown Robert E. JR | Observer for Board of Directors | Form 144 notice | 15,977 | $952k | Notice | SEC | |
| Aug 16, 2023 | Meridian Venture Partners II LP | 10% owner | Form 4 sale | 200,000 | $11.7M | 9.9% | No plan | SEC |
| Aug 16, 2023 | Meridian Venture Partners II LP | 10% Stockholder | Form 144 notice | 200,000 | $11.7M | Notice | SEC | |
| Aug 15, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 50,000 | $3.1M | 4.1% | Routine | SEC |
| Aug 15, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 22,110 | $1.4M | Notice | SEC | |
| Aug 15, 2023 | Lalwani Nikhil | President, CEO | Form 144 notice | 11,616 | $708k | Notice | SEC | |
| Aug 15, 2023 | Lalwani Nikhil | PRESIDENT & CEO | Form 4 sale | 68,282 | $4M | 16.2% | No plan | SEC |
| Aug 14, 2023 | Carey Stephen P. | SVP & CFO | Form 4 sale | 17,639 | $1.1M | 10.2% | No plan | SEC |
| Aug 14, 2023 | Pera Antonio R | Director | Form 4 sale | 3,000 | $181k | 8.2% | Routine | SEC |
| Aug 14, 2023 | Carey Stephen P. | Officer | Form 144 notice | 17,639 | $1.1M | Notice | SEC | |
| Aug 14, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 27,890 | $1.7M | Notice | SEC | |
| Aug 14, 2023 | Pera Antonio R | Director | Form 144 notice | 3,000 | $181k | Notice | SEC | |
| Aug 11, 2023 | Lalwani Nikhil | President, CEO | Form 144 notice | 56,666 | $3.4M | Notice | SEC | |
| Aug 1, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1M | 5.7% | Routine | SEC |
| Jul 21, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 23,469 | $1.2M | 1.9% | Routine | SEC |
| Jul 21, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 11,500 | $604k | Notice | SEC | |
| Jul 20, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 6,000 | $309k | Notice | SEC | |
| Jul 19, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 5,969 | $307k | Notice | SEC | |
| Jul 18, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 26,531 | $1.4M | 2.1% | Routine | SEC |
| Jul 18, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 6,700 | $347k | Notice | SEC | |
| Jul 17, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 9,831 | $502k | Notice | SEC | |
| Jul 14, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 10,000 | $504k | Notice | SEC | |
| Jul 3, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1.1M | 5.4% | Routine | SEC |
| Jun 23, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 10,000 | $515k | Notice | SEC | |
| Jun 22, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Form 4 sale | 20,000 | $1M | 5.1% | Routine | SEC |
| Jun 22, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Form 4 sale | 40,000 | $2.1M | 84.4% | Routine | SEC |
| Jun 22, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 13,500 | $694k | Notice | SEC | |
| Jun 21, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 11,843 | $616k | Notice | SEC | |
| Jun 20, 2023 | Shanmugam Muthusamy | Officer | Form 144 notice | 14,657 | $761k | Notice | SEC | |
| Dec 1, 2022 | Meridian Venture Partners II GP, L.P. | 10% owner | Form 4 sale | 200,000 | $7.7M | 9.0% | Plan not stated | SEC |
| Aug 15, 2022 | Marken James G. | SVP OPS & PROD DEV | Form 4 sale | 18,066 | $673k | 13.3% | Plan not stated | SEC |
| Aug 20, 2019 | Brown Robert E. JR | Director | Form 4 sale | 7,579 | $517k | 0.3% | Plan not stated | SEC |
| Aug 16, 2019 | Brown Robert E. JR | Director | Form 4 sale | 62,024 | $4.3M | 2.7% | Plan not stated | SEC |
| Aug 13, 2019 | Meridian Venture Partners II LP | 10% owner | Form 4 sale | 61,697 | $4.4M | 2.6% | Plan not stated | SEC |
| May 17, 2019 | Marken James G. | SVP Ops & Prod Dev | Form 4 sale | 8,907 | $629k | 12.7% | Plan not stated | SEC |
| May 15, 2019 | Przybyl Arthur | President and CEO | Form 4 sale | 30,000 | $2.1M | 12.9% | Plan not stated | SEC |
| May 14, 2019 | Marken James G. | SVP Ops & Prod Dev | Form 4 sale | 4,917 | $346k | 6.6% | Plan not stated | SEC |
| May 13, 2019 | Schrepfer Robert W | SVP - New Bus Dev & Spec Sales | Form 4 sale | 2,409 | $171k | 4.1% | Plan not stated | SEC |
| Mar 19, 2019 | Przybyl Arthur | President and CEO | Form 4 sale | 27,625 | $1.8M | 11.9% | Plan not stated | SEC |
| Mar 13, 2019 | Schrepfer Robert W | SVP - New Bus Dev & Spec Sales | Form 4 sale | 11,796 | $760k | 19.8% | Plan not stated | SEC |
| May 16, 2018 | Marshbanks Tracy | Director | Form 4 sale | 38,236 | $2.4M | 9.9% | Plan not stated | SEC |
| May 10, 2018 | Marshbanks Tracy | Director | Form 4 sale | 62,431 | $3.9M | 13.9% | Plan not stated | SEC |
| Apr 18, 2018 | Marshbanks Tracy | Director | Form 4 sale | 33,200 | $2.1M | 6.9% | Plan not stated | SEC |
| Mar 19, 2018 | Raynor Daniel | Director | Form 4 sale | 7,215 | $439k | 2.4% | Plan not stated | SEC |
| Mar 14, 2018 | Marshbanks Tracy | Director | Form 4 sale | 1,912 | $121k | 0.4% | Plan not stated | SEC |
| Mar 14, 2018 | Przybyl Arthur | President and CEO | Form 4 sale | 40,000 | $2.5M | 17.7% | Plan not stated | SEC |
| Mar 14, 2018 | Raynor Daniel | Director | Form 4 sale | 27,964 | $1.7M | 8.6% | Plan not stated | SEC |
| Mar 12, 2018 | Marshbanks Tracy | Director | Form 4 sale | 64,221 | $4M | 11.7% | Plan not stated | SEC |
| Mar 5, 2018 | Marken James G. | SVP Ops & Prod Dev | Form 4 sale | 4,177 | $259k | 6.0% | Plan not stated | SEC |
| Mar 1, 2018 | Schrepfer Robert W | SVP - New Bus Dev & Spec Sales | Form 4 sale | 28,652 | $1.8M | 68.9% | Unusual | SEC |
| Mar 1, 2018 | Przybyl Arthur | President and CEO | Form 4 sale | 23,986 | $1.5M | 10.3% | Plan not stated | SEC |
| Aug 22, 2016 | Przybyl Arthur | President and CEO | Form 4 sale | 37,455 | $2.5M | 16.3% | Plan not stated | SEC |
| Aug 8, 2016 | Schrepfer Robert W | VP Bus Dev & Con Mfg | Form 4 sale | 12,500 | $838k | 41.9% | Unusual | SEC |
| Dec 18, 2015 | Marken James G. | Vice President, Operations | Form 4 sale | 3,500 | $151k | 7.1% | Plan not stated | SEC |
| Mar 19, 2015 | Marken James G. | Vice President, Operations | Form 4 sale | 15,000 | $998k | 32.2% | Unusual | SEC |
| Mar 12, 2015 | Marshbanks Tracy | Director | Form 4 sale | 210,000 | $13.2M | 97.3% | Unusual | SEC |
| Mar 12, 2015 | Arnold Charlotte C. | Vice President and CFO | Form 4 sale | 45,000 | $2.8M | 67.8% | Unusual | SEC |
| Mar 12, 2015 | Przybyl Arthur | President and CEO | Form 4 sale | 75,000 | $4.7M | 39.6% | Unusual | SEC |
| Mar 12, 2015 | Meridian Venture Partners II LP | 10% owner | Form 4 sale | 300,000 | $18.9M | 11.3% | Plan not stated | SEC |
| Mar 12, 2015 | Raynor Daniel | Director | Form 4 sale | 200,000 | $12.6M | 38.2% | Unusual | SEC |
| Jun 18, 2014 | Marken James G. | Vice President, Operations | Form 4 sale | 5,000 | $171k | 9.7% | Plan not stated | SEC |
| May 8, 2014 | Marshbanks Tracy | Director | Form 4 sale | 1,381 | $41k | 6.0% | Plan not stated | SEC |
| Mar 21, 2014 | Marshbanks Tracy | Director | Form 4 sale | 21,767 | $684k | 72.9% | Unusual | SEC |
| Mar 20, 2014 | Brown Robert E. JR | Director | Form 4 sale | 20,922 | $672k | 0.8% | Plan not stated | SEC |
| Mar 19, 2014 | Marshbanks Tracy | Director | Form 4 sale | 25,358 | $854k | 75.2% | Unusual | SEC |
| Mar 18, 2014 | Meridian Venture Partners II GP, L.P. | 10% owner | Form 4 sale | 60,540 | $2.1M | 2.2% | Plan not stated | SEC |
| Mar 14, 2014 | Raynor Daniel | Director | Form 4 sale | 12,347 | $418k | 2.3% | Plan not stated | SEC |
| Mar 13, 2014 | Meridian Venture Partners II LP | 10% owner | Form 4 sale | 87,723 | $2.8M | 0.5% | Plan not stated | SEC |
| Mar 12, 2014 | Raynor Daniel | Director | Form 4 sale | 21,111 | $715k | 0.6% | Plan not stated | SEC |
| May 7, 2007 | Holubow Fred | Director | Form 4 sale | 7,500 | $51k | 10.9% | Plan not stated | SEC |